RecruitingNCT07306598

[18F]NIDF PET Imaging in Tau-related Diseases

Sponsor

Tianjin Medical University

Enrollment

20 participants

Start Date

Nov 1, 2025

Study Type

OBSERVATIONAL

Conditions

Alzheimer s Disease Tauopathies Neurodegenerative Disease

Summary

In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study uses a new PET scan imaging agent called [18F]NIDF to detect abnormal tau protein buildup in the brain — a hallmark of Alzheimer's disease and related conditions — to help improve diagnosis and understanding of these diseases. **You may be eligible if...** - You are between 18 and 90 years old - You have clinical signs supporting a neurodegenerative condition, OR you are a healthy volunteer for comparison - You have probable Alzheimer's disease or another form of dementia, or no known neurological disease - You or your legal guardian/caregiver can sign informed consent **You may NOT be eligible if...** - You have an allergy to the imaging agent [18F]NIDF or its components - You are unable to cooperate with the imaging procedure - You have other conditions that make the scan unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07306598

Related Trials

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol

NCT002716221 location

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location